7 benefits of having a spoonful of desi ghee with dal in summers
Tired of too many ads? go ad free now
However, with growing inclination towards health and fitness, people are gradually moving towards opting for healthier choices like adding ghee to delicacies like dal, roti or sabzis or even black tea or coffee. There's a common misconception that consuming ghee in summers can be bad for health, but according to the books of ayurveda there are several lesser known benefits of adding ghee to the summer diet is a great option for boosting overall health.
Nutrient absorption
The nourishing fats of Desi Ghee facilitate the uptake of fat-soluble vitamins such as A, D, E, and K from the dal. Your body becomes proficient at nutrient extraction from the food being consumed, leading to overall wellness.
Cool potency
Unlike popular opinion, ghee is cooling if taken in moderation. During sizzling summer days, it manages body heat, avoids dehydration, and chills the body internally.
Sustained energy
A spoonful of Desi
gives sustained energy. Its medium-chain fatty acids are absorbed by the liver directly and used as a readily available source of energy, forestalling fatigue in the scorching summer heat.
Lubricates joints
Ghee is a natural body lubricant. Daily consumption makes joints loose and mobile, and it is helpful in arthritis or joint pain.
Enhances immunity
Packed with antioxidants, ghee makes the immune system strong. Due to its anti-inflammatory nature, it aids in attacking infections and seasonal allergies, which typically occur during summers.
Skin health
Ghee is an acknowledged moisturizer. Together with dal, it aids in supporting the skin from inside, maintaining it soft and glowing even in scorching summer temperatures boosting overall health.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
an hour ago
- The Hindu
Simpler tests could slash biosimilar costs, widen patient access
Most of the drugs that we consume are called 'small molecule drugs'. Their chemical structure is reasonably simple. Disprin, for instance, has a molecular weight of around 180 daltons. There is another breed of drugs that are very large, complex molecules. For instance, the molecular weight of insulin is around 5,800 daltons and that of the monoclonal antibody remicade, about 150,000 daltons. (One dalton is equal to one-12th the mass of a carbon-12 atom.) Small molecule drugs also tend to have fixed structures that do not change for the duration of their use. In contrast, the complex molecules, which we call biologics, are produced in biological systems and therefore during their production slight variations in the structure may arise. However, these variations may have no impact on the stability of the molecule, its efficacy or its side effects. When a company produces a small molecule drug for the first time, it seeks patent protection for that drug. That is, no competitor may make that drug for several years. It is only when the drug goes 'off patent' that competitors may make it. In the absence of competition, the originator company can price the drug very high. Once there is competition, the competitor companies produce generics, which are copies of the original drug. They don't undertake the research and development to make the drug and they may not spend as much on marketing and sales, so the costs of generics are also much lower. Most of the drugs that you and I take are generics and are priced very cheaply compared to the originator drug. A good example is Sovaldi, a drug used to treat hepatitis C: it originally cost $84,000 for a 12-week course in the US but that dropped to $1,000 once Indian generic firms started making it. Largely it is generic drugs that keep us in India alive and well. Since biologics made by a generic firm will be produced by different biological systems, they may not be identical to those made by the originator company. Thus they are called biosimilars, not generics. For many years, a debate has raged over how much proof is required for a manufacturer to prove that a given biosimilar will work as well as the original biologic drug. Therefore, whereas much simpler testing was required to show that a generic small molecule was working like the originator molecule, there are more elaborate and expensive tests for biosimilars. Major drug regulators such as those of the US, the UK, and in Europe have been working to determine how they can simplify the requirements for approving a biosimilar, in view of the availability of modern analytical techniques. For example, the UK has removed animal trials and the US has planned to replace them with more human-relevant methods (like using organoids). In India, this requirement has not yet been updated although there is a proposal to waive animal studies on a case-by-case basis. Some have also argued that India should follow the practices of the UK and the US. The same holds for the more expensive clinical trials, which in the UK are currently required only in certain cases. Biosimilars need to be made less expensively while ensuring efficacy and minimal adverse effects. The larger the number of affordable biosimilars, the more options we will have for our patients. Gayatri Saberwal is a consultant at the Tata Institute for Genetics and Society.
Time of India
4 hours ago
- Time of India
At PGI, new hope to rein in type-2 diabetes
1 2 Chandigarh: Type 2 diabetes mellitus (T2DM) may not be invincible after all. Researchers are exploring the possibility of achieving remission through a combination of medication and lifestyle changes. The study, 'DiaRem-1' – recently published in the 'Indian journal of endocrinology and metabolism' – challenges the traditional view that T2DM is a permanent condition and provides evidence that remission is a feasible goal for some patients. The DiaRem-1 trial was an open-label, randomised controlled study at a single centre in India. It involved adult patients with T2DM of less than five years duration and an HbA1c level below 8.5% All participants were medicated for three months, followed by a three-month off-treatment period to assess for remission. Remission was officially defined as maintaining an HbA1c below 6.5% without any antidiabetic medication for three months. Nearly a third of the patients achieved remission. This small but powerful trial offers a cost-effective and scalable strategy that can work in outpatient clinics across India and the world. "With early, intensive treatment and continued support, many patients may no longer need diabetes medication. That's a powerful message of hope," said Dr Rama Walia, lead investigator of the study, adding: "Physical workout for an hour daily, including brisk walk, yoga or dance, was advised in the trial. Patients were kept on home-based healthy diet." Unlike other methods that rely on intensive, impractical diets or expensive surgeries, this study focused on using modern, widely available medications along with standard dietary and physical activity advice. Doctors now understand that two major culprits drive diabetes progression: glucotoxicity (too much sugar damaging beta cells) and lipotoxicity (fat accumulation impairing insulin action). By reversing these with medication and lifestyle therapy, the pancreas gets a much-needed break and, in some cases, begins to function more normally again. SWEAT & DIET MAY KEEP PILLS AWAY Chandigarh is considered the diabetic capital of India as the prevalence of prediabetes and diabetes is the highest in the country How Test Was Conducted Participants were divided into two groups: Intervention arm: 14 patients received a combination of liraglutide, dapagliflozin, and metformin. Control arm: 15 patients received vildagliptin, glimepiride, and metformin. Definition of Remission: HbA1c <6.5% for at least 3 months without medication Key Findings Remission Rate: 9 of the 29 participants (31%) achieved remission. Four from the intervention arm and five from control arm maintained HbA1c below 6.5% without treatment Weight Loss: Both groups experienced significant weight loss, as well as reductions in fat mass and body fat percentage. Intervention group had a median weight loss of -4.9 kg and the control group -3 kg, No Special Meds: Both modern and standard drugs helped when tightly managed Hope Floats: Not a cure, but a realistic and hopeful path to freedom from drugs Any Predictors Of Success? No baseline characteristics could be identified to predict which patients would achieve remission. However, those who did achieve remission tended to have a shorter duration of diabetes and greater weight loss. What's Next? PGI team is continuing research to test how long remission lasts and whether longer treatment duration might improve outcomes further Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
Time of India
6 hours ago
- Time of India
Delhi Plans State Transplant Body To Up Organ Donations
New Delhi: Health minister Pankaj Kumar Singh formally proposed the formation of a dedicated Delhi State Organ and Tissue Transplant Organisation (SOTTO) to address the growing mismatch between organ demand and availability. The proposal comes ahead of National Organ Donation Day on Aug 3, observed annually to raise awareness and encourage people to pledge their organs. Singh said the occasion underscores the urgency of building robust systems that make it easier for families to donate organs. In a letter to Union health minister JP Nadda, Singh highlighted that Delhi — home to premier tertiary hospitals and a referral hub for the northern region — urgently needed SOTTO. At present, the city lacks a state-level transplant coordination body, which experts say hinders effective organ retrieval and allocation, especially from deceased donors. You Can Also Check: Delhi AQI | Weather in Delhi | Bank Holidays in Delhi | Public Holidays in Delhi While Delhi accounted for over 4,400 transplants in 2023, only a small fraction was from deceased donors. A dedicated SOTTO is expected to improve organ registry updates, strengthen hospital coordination, and facilitate faster matching of organs with recipients. Singh said the health department, in coordination with Indian govt's Directorate General of Health Services, has already taken proactive steps to build infrastructure and deploy trained personnel. "The proposal was submitted in accordance with the Transplantation of Human Organs and Tissues Act (THOTA), and we are ready to operationalise SOTTO at a suitable location," he wrote to Nadda. Speaking to TOI, the minister said streamlining transplants through the local SOTTO would reduce preventable deaths caused by delays. "A state-level body can improve awareness, counselling, retrieval and allocation, particularly for deceased donations." The letter added that the initiative would mark a significant milestone for the organ donation movement in Delhi and build public and stakeholder trust in ethical, transparent transplantation services. Dr Satyajit Kumar, state nodal officer for the THOTA cell, said the priority was to boost deceased organ transplants. "One deceased donor can save up to eight people," he said. "Living donations are limited, so we must strengthen brain death identification, train hospital staff, simplify legal procedures and honour donor families. Public awareness campaigns and better hospital systems are key to making deceased donation a sustainable, life-saving solution. " Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
